Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease

Diabetes and Vascular Disease Research

Volumn 12, Issue 4, 2015, Pages 249-257

  McGill, Janet B ^a   Yki Järvinen, Hannele ^b   Crowe, Susanne ^c   Woerle, Hans Juergen ^c   Von Eynatten, Maximilian ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

chronic kidney disease; dipeptidyl peptidase 4 inhibitor; linagliptin; Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LINAGLIPTIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SHORT ACTING INSULIN; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYSTITIS; DIABETIC NEPHROPATHY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; ENURESIS; FEMALE; GLOMERULONEPHRITIS; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMATURIA; HUMAN; HYDRONEPHROSIS; HYPERTENSION; HYPOGLYCEMIA; KETONURIA; KIDNEY COLIC; KIDNEY CYST; KIDNEY DISEASE; KIDNEY PAIN; LEUKOCYTURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MORBIDITY; NEPHROLITHIASIS; NEUROGENIC BLADDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; PROSPECTIVE STUDY; PROTEINURIA; PYURIA; RANDOMIZED CONTROLLED TRIAL; SEVERE RENAL IMPAIRMENT; UNSPECIFIED SIDE EFFECT; URETER STONE; URINARY TRACT DISEASE; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION; UROLITHIASIS; WEIGHT CHANGE; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; METABOLISM; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOSIDE HYDROLASE INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LINAGLIPTIN; MALE; METFORMIN; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84936993420     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164115579001     Document Type: Article

References (29)

1. Atkins RC,. The epidemiology of chronic kidney disease. Kidney Int 2005; 67: S14-S18.
2. Koro CE, Lee BH, Bowlin SJ,. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009; 31: 2608-2617.
3. US Renal Data System. 2013 USRDS annual data report: atlas of end-stage renal disease in the United States, vol. 2, http://www.usrds.org/2013/pdf/v2-00-intro-13.pdf (accessed4 August 2014).
4. Kalaitzidis RG, Sarafidis PA, Bakris GL,. Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des 2009; 15: 529-536.
5. Cavanaugh KL,. Diabetes management issues for patients with chronic kidney disease. Clin Diabetes 2007; 25: 90-97.
6. Byetta Summary of Product Characteristics. AstraZeneca., http://www.medicines.org.uk/emc/medicine/19257 (accessed 4 August 2014).
7. Victoza Summary of Product Characteristics. Novo Nordisk., http://www.medicines.org.uk/emc/medicine/21986 (accessed 4 August 2014).
8. Lyxumia Summary of Product Characteristics. Sanofi., http://www.medicines.org.uk/emc/medicine/27406/SPC/Lyxumia+20+micrograms+solution+for+injection/ (accessed 4 August 2014).
9. Inzucchi SE, Bergenstal RM, Buse JB,. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
10. Riddle MC, Rosenstock J, Gerich J,. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
11. Rosenstock J, Davies M, Home PD,. A randomised 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416.
12. McGill JB,. Linagliptin for type 2 diabetes mellitus: A review of the pivotal clinical trials. Ther Adv Endocrinol Metab 2012; 3: 113-124.
13. Graefe-Mody U, Rose P, Retlich S,. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol 2012; 74: 75-85.
14. Trajenta Summary of Product Characteristics. Boehringer Ingelheim Limited., http://www.medicines.org.uk/emc/medicine/25000/SPC/Trajenta+5+mg+film-coated+tablets/ (accessed 4 August 2014).
15. Gomis R, Espadero RM, Jones R,. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 653-661.
16. Del Prato S, Barnett AH, Huisman H,. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011; 13: 258-267.
17. Taskinen MR, Rosenstock J, Tamminen I,. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 65-74.
18. Owens DR, Swallow R, Dugi KA,. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011; 28: 1352-1361.
19. Yki-Järvinen H, Rosenstock J, Durán-Garcia S,. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a â©3/452-week randomized, double-blind study. Diabetes Care 2013; 36: 3875-3881.
20. McGill JB, Sloan L, Newman J,. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013; 36: 237-244.
21. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis 2012; 60: 850-886.
22. Chan JC, Scott R, Arjona Ferreira JC,. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008; 10: 545-555.
23. Nowicki M, Rychlik I, Haller H,. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011; 13: 523-532.
24. Williams ME, Garg R,. Glycemic management in ESRD and earlier stages of CKD. Am J Kidney Dis 2014; 63: S22-S38.
25. Barnett AH, Huisman H, Jones R,. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382: 1413-1423.
26. Marney A, Kunchakarra S, Byrne L,. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010; 56: 728-733.
27. Groop PH, Cooper ME, Perkovic V,. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013; 36: 3460-3468.
28. Ahrén B, Schweizer A, Dejager S,. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 1236-1243.
29. Khan R,. Weight gain and insulin therapy. Br J Diabetes Vasc Dis 2004; 4: 264-267.